Results 191 to 200 of about 21,980,265 (388)
Objective Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.
Moritz A. Loeffler +8 more
wiley +1 more source
Clarify: Software for Interpreting and Presenting Statistical Results [PDF]
Clarify is a program that uses Monte Carlo simulation to convert the raw output of statistical procedures into results that are of direct interest to researchers, without changing statistical assumptions or requiring new statistical models.
Gary King +2 more
core +1 more source
Impact of interactivity on learning outcome in online learning settings: Ordinal logit model
Byung–Hak Leem
openalex +1 more source
Analysis of multivariate longitudinal substance use outcomes using multivariate mixed cumulative logit model [PDF]
Xiaolei Lin +2 more
openalex +1 more source
Probabilistic Lesion Mapping to Optimize Thalamotomy Targets for Focal Hand Dystonia
Objective Focal hand dystonia (FHD) severely impairs task‐specific motor control, yet the optimal surgical target for stereotactic intervention remains uncertain. This study aimed to identify the precise thalamic lesion site associated with symptomatic improvement and to clarify its network connectivity. Methods We retrospectively analyzed 164 patients
Masahiko Nishitani +12 more
wiley +1 more source
Generalized additive logit models for clinical prediction. [PDF]
McIntosh CN.
europepmc +1 more source
Identifying and Forecasting the Turning Points of the Belgian Business Cycle with Regime-Switching and Logit Models [PDF]
This paper seeks to elaborate econometric models that can be used to forecast the turning points of the Belgian business cycle. We begin by suggesting three reference cycle, which we hope will fill the void of an official reference chronology for Belgium.
Fati, SHADMAN-MEHTA +2 more
core
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami +10 more
wiley +1 more source

